Weekly Roundup: November 9-13

November 13, 2020
Morgan Petronelli

ICYMI, some of the content featured this week includes narrow-spectrum antibiotics for acne, an AI-powered rosacea diagnostic tool, a new topical acne treatment, plus more.

In case you missed it, some of this week’s featured content includes stories on new artificial intelligence-powered diagnostic tool for rosacea, clascoterone cream 1% and how it is the first acne drug with a new mechanism of action to win U.S. Food and Drug Administration approval in the last 40 years. Also, articles on how systemic therapies for psoriasis are not age dependent, up and coming vehicles within the rosacea treatment sphere, how narrow-spectrum antibiotics have shown a low propensity for development of antimicrobial resistance while also effectively treating acne, plus more.

POLL: Do you consider mental health in your patient's treatment plan?

The Mainstream Patient: November 11

This week’s edition of The Mainstream Patient features stories on a cryotherapy hairbrush, how to treat comedones, humectants and lanolin for moisturization, plus more.

AI-powered diagnostic tool accurately identifies rosacea

A new artificial intelligence-powered diagnostic tool, Ros-NET, was able to accurately identify rosacea, making way for further development of the technology to aid in diagnosis of the skin condition, according to a recent study.

Clascoterone cream 1% targets androgen receptors

The topical cream is the first acne drug with a new mechanism of action to win FDA approval in the last 40 years.

Systemic psoriasis therapies not age-dependent

Comorbidities, co-medication, organ impairment, functional deterioration and frailty make treatment plans challenging for older psoriasis patients. However, these patients should not be precluded but will require more extensive evaluation and assessment, according to a recent study.

Safety profiles differentiate conventional therapies

In a recent study, psoriasis drugs showed widely variable drug survival rates, owing to differences in safety, efficacy, patient satisfaction and other factors. However, concerns linger over potential to cause long-term cumulative organ toxicity.

Venetoclax monotherapy for cutaneous BPDCN

B-cell lymphoma-2 inhibitor venetoclax has shown in clinical studies to improve symptoms with minimal toxicity in patients with cutaneous blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer that can be rapidly fatal without treatment.

Narrow-spectrum antibiotics viable treatment option for acne

Perceptions of antibiotics and potential antibiotic resistance have caused some physicians to be wary of the drug class when prescribing an acne treatment regimen. However, narrow-spectrum antibiotics have shown a low propensity for development of antimicrobial resistance while also effectively treating acne.

Data describes BPDCN’s clinical, biological features and patient outcomes

A recently published article details the clinical and biological features, and patient outcomes of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematopoietic malignancy.

Treatment improves QOL for patients with acne

Quality of life could play role in assessing acne patient care. According to recent study’s results, researchers saw a four-to-five-fold QOL improvement versus baseline over a full treatment course of isotretinoin.

HIPAA, COVID-19 and jail

David J. Goldberg, M.D., J.D., explains how a terminated employee can violate HIPAA if they access medical records of other associates at their former place of work, even if they find out one of those associates had COVID-19 and did not disclose it to the office.

New vehicles improve tolerability, acceptability

A variety of new vehicles designed to improve tolerability and cosmetic acceptability are providing rosacea patients with multiple viable treatment options.

Related Content:

News